Efficacy and Safety of CDP870 and Methotrexate Compared to Methotrexate Alone in Subjects With Rheumatoid Arthritis
Status:
Completed
Trial end date:
2004-01-01
Target enrollment:
Participant gender:
Summary
The main purpose of the study was to determine the efficacy of CDP870 in treating RA
signs/symptoms in patients who were partial responders to MTX. Other purposes were to show
additional efficacy without increased toxicity and the immunogenic response to CDP870 during
combined CDP870 and MTX therapy.